Discovery and Optimization of 2 H -1λ 2 -Pyridin-2-one Inhibitors of Mutant Isocitrate Dehydrogenase 1 for the Treatment of Cancer
Jason M. Rohde,Surendra Karavadhi,Rajan Pragani,Li Liu,Yuhong Fang,Weihe Zhang,Andrew McIver,Hongchao Zheng,Qingyang Liu,Mindy I. Davis,Daniel J. Urban,Tobie D. Lee,Dorian M. Cheff,Melinda Hollingshead,Mark J. Henderson,Natalia J. Martinez,Kyle R. Brimacombe,Adam Yasgar,Wei Zhao,Carleen Klumpp-Thomas,Sam Michael,Joseph Covey,William J. Moore,Gordon M. Stott,Zhuyin Li,Anton Simeonov,Ajit Jadhav,Stephen Frye,Matthew D. Hall,Min Shen,Xiaodong Wang,Samarjit Patnaik,Matthew B. Boxer
DOI: https://doi.org/10.1021/acs.jmedchem.1c00019
IF: 8.039
2021-04-06
Journal of Medicinal Chemistry
Abstract:Neomorphic mutations in isocitrate dehydrogenase 1 (IDH1) are oncogenic for a number of malignancies, primarily low-grade gliomas and acute myeloid leukemia. We report a medicinal chemistry campaign around a 7,7-dimethyl-7,8-dihydro-2<i>H</i>-1λ<sup>2</sup>-quinoline-2,5(6<i>H</i>)-dione screening hit against the R132H and R132C mutant forms of isocitrate dehydrogenase (IDH1). Systematic SAR efforts produced a series of potent pyrid-2-one mIDH1 inhibitors, including the atropisomer <b>(+)-119</b> (<b>NCATS</b>-<b>SM5637</b>, <b>NSC 791985</b>). In an engineered mIDH1-U87-xenograft mouse model, after a single oral dose of 30 mg/kg, 16 h post dose, between 16 and 48 h, <b>(+)-119</b> showed higher tumoral concentrations that corresponded to lower 2-HG concentrations, when compared with the approved drug AG-120 (ivosidenib).The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.1c00019?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00019</a>.Molecular formula strings of all compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00019/suppl_file/jm1c00019_si_001.csv">CSV</a>)Spectroscopic data (<sup>1</sup>H NMR, LC/MS) for representative compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00019/suppl_file/jm1c00019_si_002.pdf">PDF</a>)This article has not yet been cited by other publications.
chemistry, medicinal